{"id":389,"date":"2025-11-10T13:09:18","date_gmt":"2025-11-10T13:09:18","guid":{"rendered":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/heidelberg-pharma-annonce-des-progres-encourageants-dans-le-traitement-du-myelome-multiple\/"},"modified":"2025-11-10T13:09:18","modified_gmt":"2025-11-10T13:09:18","slug":"heidelberg-pharma-annonce-des-progres-encourageants-dans-le-traitement-du-myelome-multiple","status":"publish","type":"post","link":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/heidelberg-pharma-annonce-des-progres-encourageants-dans-le-traitement-du-myelome-multiple\/","title":{"rendered":"Heidelberg Pharma annonce des progr\u00e8s encourageants dans le traitement du my\u00e9lome multiple"},"content":{"rendered":"<p>Heidelberg Pharma a rapport\u00e9 des progr\u00e8s encourageants dans son essai de phase 2\/2a du HDP-101, un m\u00e9dicament exp\u00e9rimental pour le my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire. Deux patients dans le groupe 8 ont atteint une r\u00e9mission compl\u00e8te, sans cellules tumorales d\u00e9tectables dans le sang ou la moelle osseuse. Sept patients ont \u00e9t\u00e9 \u00e9valu\u00e9s \u00e0 une dose de 140 \u00b5g\/kg. Tous ont montr\u00e9 un bon profil de s\u00e9curit\u00e9 et de tol\u00e9rance, sans toxicit\u00e9s limit\u00e9es observ\u00e9es. Quatre patients ont montr\u00e9 une activit\u00e9 biologique, y compris une r\u00e9ponse partielle, une tr\u00e8s bonne r\u00e9ponse partielle et deux r\u00e9missions compl\u00e8tes. Le Dr Andr\u00e1s Strassz, directeur m\u00e9dical de Heidelberg Pharma, a d\u00e9clar\u00e9 : &#8220;Nous sommes tr\u00e8s satisfaits des donn\u00e9es obtenues jusqu&#8217;\u00e0 pr\u00e9sent. Plusieurs patients de diff\u00e9rents groupes ont montr\u00e9 des r\u00e9ponses objectives et une activit\u00e9 anti-tumorale prometteuse. Observer deux r\u00e9missions compl\u00e8tes est une validation encourageante de notre approche th\u00e9rapeutique.&#8221; Il a ajout\u00e9 : &#8220;Nous avons d\u00e9j\u00e0 vu une r\u00e9mission compl\u00e8te chez un patient du groupe 5, mais dans le groupe 8, l&#8217;apparition de la r\u00e9ponse a \u00e9t\u00e9 plus rapide. Ces r\u00e9sultats renforcent notre confiance dans le potentiel th\u00e9rapeutique du HDP-101 chez les patients lourdement pr\u00e9trait\u00e9s atteints de my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire, et nous passons maintenant au groupe 9 avec une dose augment\u00e9e de 175 \u00b5g\/kg pour poursuivre son \u00e9valuation clinique.&#8221; L&#8217;\u00e9tude de phase 2\/2a est une \u00e9tude non randomis\u00e9e, en ouvert, avec escalade de dose, recrutant des patients atteints de my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ou d&#8217;autres troubles des plasmocytes exprimant le BCMA. Elle vise \u00e0 \u00e9valuer la s\u00e9curit\u00e9, la tol\u00e9rance, la pharmacocin\u00e9tique et l&#8217;efficacit\u00e9 pr\u00e9liminaire du HDP-101.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Heidelberg Pharma a rapport\u00e9 des progr\u00e8s encourageants dans son essai de phase 2\/2a du HDP-101, un m\u00e9dicament exp\u00e9rimental pour le [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":390,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[414],"tags":[],"class_list":["post-389","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles"],"_links":{"self":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/comments?post=389"}],"version-history":[{"count":0,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/389\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media\/390"}],"wp:attachment":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media?parent=389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/categories?post=389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/tags?post=389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}